Neuroelectrics Announces Results of Telemedicine Pilot Depression Study with Starstim tDCS Therapy
View the full release here: https://www.businesswire.com/news/home/20240307614300/en/
- View the full release here: https://www.businesswire.com/news/home/20240307614300/en/
The preprint, titled “Multichannel tDCS with Advanced Targeting for Major Depressive Disorder: A Tele-Supervised At-Home Pilot Study,” highlights results from a multicenter, open-label feasibility telemedicine pilot study that studied the efficacy, safety, and feasibility of home-based tDCS using Starstim to target the L-DLPFC. - The study was conducted across multiple centers and involved 35 participants diagnosed with medication-resistant MDD to evaluate tDCS administered at home using Neuroelectrics’ Starstim device.
- Results from this study highlight the safety and feasibility of at-home tDCS, with nearly 90% of participants completing the treatment without experiencing any adverse effects.
- “We’re excited to announce the results of our telemedicine pilot study, showcasing the transformative potential of at-home tDCS therapy with our Starstim device in managing MDD,” said Ana Maiques, CEO & Co-Founder, Neuroelectrics.